• Aucun résultat trouvé

Document Number: 1233402 Version: 3

N/A
N/A
Info
Télécharger
Protected

Academic year: 2022

Partager "Document Number: 1233402 Version: 3"

Copied!
1
0
0

Chargement.... (Voir le texte intégral maintenant)

Texte intégral

(1)AbbVie Files Form S-4 NORTH CHICAGO, ILLINOIS, U.S.A., August 21, 2014 – AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a Form S-4 Registration Statement with the U.S. Securities and Exchange Commission (“SEC”). AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie’s website at www.abbvieinvestor.com. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC’s home page at http://www.sec.gov. Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investors Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A. SOURCE AbbVie Inc. CONTACT: AbbVie Inc., 1-847-938-8745. Document Number: 1233402. Version: 3. WorldReginfo - c5b4de96-0613-4f1a-bbc3-e56c095b0b70. ###.

(2)

Références

Télécharger maintenant ( PDF - 1 Page - 190.13 KB )

Documents relatifs

Document Number: 1233402 Version: 3

Securities and Exchange Commission “SEC” amending the April 25, 2016 announcement regarding the Agreement and Plan of Merger the “Merger Agreement” with Stemcentrx, Inc., a

AbbVie Files Form 10-Q

AbbVie makes available free of charge on its website its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16

These materials may be obtained electronically by accessing the SEC’s home page at http://www.sec.gov

AbbVie makes available free of charge on its website its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16

AbbVie Files Form 8-K

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Makes SEC Filings Relating To Its Previously Announced Agreement and Plan of Reorganization with Pharmacyclics, Inc.

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Files Documentation with the Securities and Exchange Commission In Connection With a Registered Debt Offering

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Files a Current Report on Form 8-K

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Files Form 8-K

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section